Welcome Guest

Sign In

Register

* OPHTHALMOLOGY WEB

Search OphthalmologyWeb

Home

Cataract

Cornea Glaucoma Refractive

Retina

Practice Management

News

Events

Articles

Product Center

Featured Products

Videos

News FDA Approves LUMIFY™, a Brimonidine OTC for Ocular Redness

FDA Approves LUMIFY™, a Brimonidine OTC for **Ocular Redness**

Posted: January 22, 2018

Tweet

Share Email

Comments

New Jersey-based eye heal h company Bausch + Lomb has announced last week of the U.S. Food and Drug Administration (FDA) approval of LUMIFY™ (brimonidine tartrate ophthalmic solu ion 0.025%). It is the first over-the-counter eye drop developed with low-dose brimonidine tartrate for the treatment of ocular redness. Brimonidine has been clinically proven to be safe and effective since its initial approval as a prescription medication in 1996 for intraocular pressure (IOP) reduc ion in glaucoma patients, and is available at higher doses in prescription oph halmic products.



"Ocular redness is a common, non-specific sign hat brings many patients into our offices," said Melissa Toyos, M.D., general oph halmologist, dry eye specialist, cataract surgeon and facial cosmetic surgeon at Toyos Clinic. "LUMIFY specifically reduces redness due to minor irritations while alleviating concerns of rebound hyperemia, dependency or tachyphylaxis—conditions that can lead to serious or permanent damage to the eye. I am excited to recommend LUMIFY to my patients to effectively relieve redness and help them get 'camera ready'."

To support approval of an OTC indication for LUMIFY, six clinical studies were conducted in over 600 patients to evaluate the safety and efficacy of low-dose brimonidine tartrate in relieving ocular redness, including studies with both pediatric and geriatric subjects. The double-blinded, randomized, placebo-controlled Phase 3 efficacy study showed that 95% of subjects reported significant symptom improvement at 1 minute, while 79% of respondents maintained significant redness reduc ion at 8 hours. The strong efficacy and safety profile of brimonidine tartrate 0.025% includes not only significant redness reduction for up to 8 hours, but low-risk of allergic reac ions among all patient groups

"LUMIFY is an important addition to the diverse Bausch + Lomb portfolio of eye health products, and demonstrates our con inued commitment to introducing new innovative products that meet the evolving needs of eve care professionals and the patients they treat." said Joseph Gordon, president, Consumer Healthcare and Vision Care, Bausch + Lomb.

LUMIFY will be available for purchase in major retailers in the second quarter of 2018.

See the full press release from Bausch + Lomb

Source: Bausch + Lomb

Comments

Selected Products

Quick Quiz

The most likely diagnosis is:



- a. congenital glaucoma
- b. bir h trauma
- c. hypotony
- d. enlarged corneal nerves

check the answer



Featured Products



SPECTRALIS Diagnostic Imaging Platform

A modular and upgradeable ophthalmic

view product



Selecta Trio™ YAG Laser, SLT Photocoagulation

The Lumenis Selecta® Trio™ ..

view product

view all featured products »

Follow OphthalmologyWeb

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox


Your Email Address

Like us

Follow us



8/16/22, 11:22 AM FDA Approves LUMIFY™, a Brimonidine OTC for Ocular Redness | OphthalmologyWeb: The Ultimate Online Resource for Opht...



OphthalmologyWeb: The Ultimate Online Resource for Ophthalmologists!

Product Center	View All Articles	Newsletter Signup
New Product Profiles	Featured Articles	Newsletter Archives
	News	Advertise With Us
	Events	View our Media Kit
	Resources	
	Quick Picks	
		See our other sites »
		New Product Profiles Featured Articles News Events Resources

Selected Products

